|
JPS4875564A
(enExample)
|
1972-01-08 |
1973-10-11 |
|
|
|
JPS4988862A
(enExample)
|
1972-12-29 |
1974-08-24 |
|
|
|
US4883658A
(en)
|
1986-04-28 |
1989-11-28 |
Holly Frank J |
Ophthalmic solution for treatment of dry-eye syndrome
|
|
US4804539A
(en)
|
1986-07-28 |
1989-02-14 |
Liposome Technology, Inc. |
Ophthalmic liposomes
|
|
JPH0788376B2
(ja)
|
1986-09-02 |
1995-09-27 |
エーザイ株式会社 |
光学活性α−トコトリエノ−ルの製造方法
|
|
US4914088A
(en)
|
1987-04-02 |
1990-04-03 |
Thomas Glonek |
Dry eye treatment solution and method
|
|
US5278151A
(en)
|
1987-04-02 |
1994-01-11 |
Ocular Research Of Boston, Inc. |
Dry eye treatment solution
|
|
JP2685785B2
(ja)
|
1988-03-11 |
1997-12-03 |
エーザイ株式会社 |
光学活性α−トコトリエノールの製造方法
|
|
JPH029875A
(ja)
|
1988-03-16 |
1990-01-12 |
Bio Ind Kyokai |
トコフェロール及びトコトリエノールの製造方法
|
|
US5075104A
(en)
|
1989-03-31 |
1991-12-24 |
Alcon Laboratories, Inc. |
Ophthalmic carboxy vinyl polymer gel for dry eye syndrome
|
|
US5157132A
(en)
|
1990-05-18 |
1992-10-20 |
Carotech Associates |
Integrated process for recovery of carotenoids and tocotrienols from oil
|
|
ZA912797B
(en)
|
1990-05-29 |
1992-12-30 |
Boston Ocular Res |
Dry eye treatment process and solution
|
|
DE69115990T2
(de)
|
1990-05-29 |
1996-05-30 |
Ocular Res Of Bonton Inc |
Zusammensetzung zur Behandlung von Dry Eye Erkrankungen
|
|
ZA927277B
(en)
|
1991-10-02 |
1993-05-19 |
Boston Ocular Res |
Dry eye treatment process and solution.
|
|
CA2124086A1
(en)
|
1991-11-22 |
1993-05-27 |
Ronald H. Lane |
Tocotrienols and tocotrienol-like compounds and methods for their use
|
|
US5318993A
(en)
*
|
1993-04-16 |
1994-06-07 |
Bristol-Myers Squibb Company |
Antihyperlipidemic benzoquinones
|
|
EP0708646A1
(en)
|
1994-05-06 |
1996-05-01 |
Alcon Laboratories, Inc. |
Use of vitamin e tocopheryl derivatives in ophthalmic compositions
|
|
ES2176354T3
(es)
|
1994-12-28 |
2002-12-01 |
Janssen Pharmaceutica Nv |
Uso de nebivolol como agente anti-aterogenico.
|
|
US6232060B1
(en)
|
1996-01-19 |
2001-05-15 |
Galileo Laboratories, Inc. |
Assay system for anti-stress agents
|
|
US5801159A
(en)
|
1996-02-23 |
1998-09-01 |
Galileo Laboratories, Inc. |
Method and composition for inhibiting cellular irreversible changes due to stress
|
|
WO1999038859A1
(en)
|
1998-01-29 |
1999-08-05 |
Eastman Chemical Company |
Methods for separating a tocol from a tocol-containing mixture
|
|
WO2000078296A2
(en)
|
1999-06-17 |
2000-12-28 |
Basf Aktiengesellschaft |
Tocotrienol and/or tocotrienol derivatives for the treatment or prophylaxis of glutamate- and/or calcium-induced disorders
|
|
US6395915B1
(en)
|
1999-09-10 |
2002-05-28 |
Technikrom, Inc. |
Method for producing purified tocotrienols and tocopherols using liquid chromatography
|
|
US6528042B1
(en)
|
1999-10-08 |
2003-03-04 |
Galileo Laboratories, Inc. |
Compositions of flavonoids for use as cytoprotectants and methods of making and using them
|
|
US6426362B1
(en)
|
1999-10-08 |
2002-07-30 |
Galileo Laboratories, Inc. |
Formulations of tocopherols and methods of making and using them
|
|
MY127451A
(en)
|
1999-11-04 |
2006-12-29 |
Malaysian Palm Oil Board |
A method of chromatographic isolation for vitamin e isomers
|
|
DE10034233A1
(de)
|
2000-07-14 |
2002-01-24 |
Basf Ag |
Tocotrienolchinon-Cyclisierungsprodukte
|
|
GB0023555D0
(en)
*
|
2000-09-26 |
2000-11-08 |
Inst Of Ophthalmology |
Improvements in and relating to treatments for eye disease
|
|
US7034054B2
(en)
|
2000-12-15 |
2006-04-25 |
Galileo Pharmaceuticals, Inc. |
Methods for the prevention and treatment of cerebral ischemia using non-alpha tocopherols
|
|
WO2002047680A2
(en)
|
2000-12-15 |
2002-06-20 |
Galileo Laboratories, Inc. |
Use of tocopherol, metabolites or derivatives thereof or flavonoid metabolites or derivatives thereof in the manufacture of a medicament for the treatment of tissue ischemia
|
|
US6838104B2
(en)
|
2000-12-20 |
2005-01-04 |
Archer Daniels Midland Company |
Process for the production of tocotrienols
|
|
US6608196B2
(en)
|
2001-05-03 |
2003-08-19 |
Galileo Pharmaceuticals, Inc. |
Process for solid supported synthesis of pyruvate-derived compounds
|
|
MXPA04001555A
(es)
|
2001-08-21 |
2004-10-27 |
Galileo Pharmaceuticals Inc |
Composiciones enriquecidas con tocoferol y mejoramiento de sintomas inflamatorios.
|
|
AU2002352726A1
(en)
|
2001-11-15 |
2003-06-10 |
Galileo Laboratories, Inc. |
Formulations and methods for treatment or amelioration of inflammatory conditions
|
|
US6667330B2
(en)
|
2002-01-31 |
2003-12-23 |
Galileo Pharmaceuticals, Inc. |
Furanone derivatives
|
|
US7078541B2
(en)
|
2002-02-07 |
2006-07-18 |
Galileo Pharmaceuticals, Inc. |
Benzofuran derivatives
|
|
US6653346B1
(en)
|
2002-02-07 |
2003-11-25 |
Galileo Pharmaceuticals, Inc. |
Cytoprotective benzofuran derivatives
|
|
ATE328283T1
(de)
|
2002-07-01 |
2006-06-15 |
Santhera Pharmaceuticals Ch |
Screeningverfahren und verbindungen zur behandlung von friedreich ataxia
|
|
JP4599292B2
(ja)
|
2002-10-30 |
2010-12-15 |
エジソン ファーマシューティカルズ， インコーポレイテッド |
物理的−化学的特性に基づく治療用化合物の同定
|
|
US7015243B2
(en)
*
|
2003-08-28 |
2006-03-21 |
Allergan, Inc. |
Cyclohexyl prostaglandin analogs as EP4-receptor agonists
|
|
CA2583084C
(en)
|
2003-09-19 |
2010-12-07 |
Galileo Pharmaceuticals, Inc. |
7,8-bicycloalkyl-chroman derivatives
|
|
US20050074447A1
(en)
*
|
2003-10-01 |
2005-04-07 |
Papas Andreas M. |
Treatment for diabetic microvascular and macrovascular complications
|
|
WO2005035491A2
(en)
|
2003-10-10 |
2005-04-21 |
Yasoo Health, Inc. |
PROCESS FOR SYNTHESIZING d-TOCOTRIENOLS FROM 2- VINYLCHROMANE COMPOUND
|
|
US8182990B2
(en)
|
2004-03-18 |
2012-05-22 |
Rusk Intellectual Reserve Ag |
Method for diagnosing or predicting susceptibility to optic neuropathy
|
|
DE602004022523D1
(de)
|
2004-07-02 |
2009-09-24 |
Novagali Pharma Sa |
Verwendung von Emulsionen zur intra- und periocularen Injection
|
|
US7393662B2
(en)
|
2004-09-03 |
2008-07-01 |
Centocor, Inc. |
Human EPO mimetic hinge core mimetibodies, compositions, methods and uses
|
|
ES2532997T3
(es)
|
2005-04-22 |
2015-04-06 |
Elizabeth Stuart |
Uso de tocotrienoles de vitamina E para la inhibición del patógeno intracelular obligado Chlamydia
|
|
EP2564842A1
(en)
*
|
2005-06-01 |
2013-03-06 |
Edison Pharmaceuticals, Inc. |
Redox-active therapeutics for treatment of mitochondrial diseases and other conditions and modulation of energy biomarkers
|
|
JP2009508867A
(ja)
|
2005-09-15 |
2009-03-05 |
エジソン ファーマシューティカルズ， インコーポレイテッド |
ミトコンドリア病および関連した様態の治療ならびにエネルギーバイオマーカーの調節のための酸化還元活性治療剤のテイル改変体
|
|
CA2850858A1
(en)
|
2005-09-16 |
2007-04-05 |
Allergan, Inc. |
Compositions and methods for the intraocular transport of therapeutic agents
|
|
JP5374162B2
(ja)
*
|
2006-02-22 |
2013-12-25 |
エジソン ファーマシューティカルズ， インコーポレイテッド |
ミトコンドリア病および他の症状の処置のためのレドックス活性化治療の側鎖変異体およびエネルギーバイオマーカーの調節
|
|
CN101610782A
(zh)
|
2007-01-10 |
2009-12-23 |
爱迪生药物公司 |
使用具有促红细胞生成素或血小板生成素活性的化合物治疗呼吸链紊乱
|
|
WO2008157747A1
(en)
|
2007-06-21 |
2008-12-24 |
The Jackson Laboratory |
Use of inhibition of exonuclease 1 in methods for therapy and diagnostic of neurodegenerative diseases, eye diseases, and mitochondrial disorders
|
|
US20100209436A1
(en)
|
2007-07-03 |
2010-08-19 |
Andreas Reichert |
Method for treating diseases related to mitochondrial dysfunction
|
|
ES2507078T3
(es)
|
2007-08-16 |
2014-10-14 |
Santen Pharmaceutical Co., Ltd |
Formulaciones de rapamicina para tratamiento de la degeneración macular relacionada con la edad
|
|
US8075909B2
(en)
|
2007-09-04 |
2011-12-13 |
University Of Florida Research Foundation, Incorporated |
Contact lens based bioactive agent delivery system
|
|
CA2704473C
(en)
|
2007-11-06 |
2016-10-04 |
Edison Pharmaceuticals, Inc. |
4-(p-quinonyl)-2-hydroxybutanamide derivatives for treatment of mitochondrial diseases
|
|
WO2009088572A2
(en)
|
2008-01-07 |
2009-07-16 |
Centocor, Inc. |
Method of treating erythropoietin hyporesponsive anemias
|
|
EP2237664A4
(en)
|
2008-01-08 |
2013-05-22 |
Edison Pharmaceuticals Inc |
(HET) ARYL-p-CHINONE DERIVATIVES FOR THE TREATMENT OF OCHONDRIAL DISEASES
|
|
US20110046156A1
(en)
|
2008-03-05 |
2011-02-24 |
Miller Guy M |
Treatment of hearing and balance impairments with redox-active therapeutics
|
|
WO2009111576A2
(en)
|
2008-03-05 |
2009-09-11 |
Edison Pharmaceuticals, Inc. |
2-SUBSTITUTED-p-QUINONE DERIVATIVES FOR TREATMENT OF OXIDATIVE STRESS DISEASES
|
|
WO2009140382A2
(en)
|
2008-05-15 |
2009-11-19 |
Edison Pharmaceuticals, Inc. |
Treatment of hearing and balance impairments using compounds having erythropoietin activity
|
|
CA2724841A1
(en)
|
2008-05-22 |
2009-11-26 |
Edison Pharmaceuticals, Inc. |
Treatment of mitochondrial diseases with an erythropoietin mimetic
|
|
US8716486B2
(en)
|
2008-06-25 |
2014-05-06 |
Edison Pharmaceuticals, Inc. |
2-heterocyclylaminoalkyl-(p-quinone) derivatives for treatment of oxidative stress diseases
|
|
US20100010100A1
(en)
|
2008-07-09 |
2010-01-14 |
Hinman Andrew W |
Dermatological compositions with anti-aging and skin even-toning properties
|
|
US20100029784A1
(en)
|
2008-07-30 |
2010-02-04 |
Hinman Andrew W |
Naphthoquinone compositions with anti-aging, anti-inflammatory and skin even-toning properties
|
|
MX363223B
(es)
|
2008-09-10 |
2019-03-15 |
Bioelectron Tech Corp |
Tratamiento de trastornos generalizados del desarrollo con terapeuticos con actividad redox.
|
|
JP5731980B2
(ja)
|
2008-10-09 |
2015-06-10 |
ラムズコア， インコーポレイテッド |
ドライアイ症候群の処置のための組成物および方法
|
|
CA2740773A1
(en)
|
2008-10-14 |
2010-04-22 |
Edison Pharmaceuticals, Inc. |
Treatment of oxidative stress disorders including contrast nephropathy, radiation damage and disruptions in the function of red cells
|
|
CA2974482C
(en)
|
2008-10-28 |
2019-10-29 |
Bioelectron Technology Corporation |
High purity alpha tocotrienol quinone and processes for preparing same
|
|
NO2424495T3
(enExample)
|
2009-04-28 |
2018-06-16 |
|
|
|
US20100273892A1
(en)
|
2009-04-28 |
2010-10-28 |
Miller Guy M |
Formulations of tocotrienol quinones for the treatment of ophthalmic diseases
|
|
JP2012525398A
(ja)
|
2009-04-28 |
2012-10-22 |
アンペア ライフ サイエンシーズ，インコーポレイテッド |
眼科障害を治療するためのトコトリエノールの局所、眼周囲または眼内使用
|
|
MX2011013558A
(es)
|
2009-06-25 |
2012-04-30 |
Ampere Life Sciences Inc |
Tratamiento del trastorno pervasivo del desarrollo con tocotrienoles o extractos de tocotrienoles enriquecidos.
|
|
SI2470168T1
(en)
|
2009-08-26 |
2018-05-31 |
Bioelectron Technology Corporation |
Procedures for the prevention and treatment of brain ischemia
|
|
WO2011041452A2
(en)
|
2009-10-01 |
2011-04-07 |
Ampere Life Sciences, Inc. |
Mouse model for identifying compounds for the treatment of oxidative stress
|
|
WO2011082355A1
(en)
|
2009-12-31 |
2011-07-07 |
Edison Pharmaceuticals, Inc. |
Treatment of leigh syndrome and leigh-like syndrome with tocotrienol quinones
|
|
WO2011113018A1
(en)
|
2010-03-12 |
2011-09-15 |
Ampere Life Sciences, Inc. |
Measurement and control of biological time
|
|
EA201201374A1
(ru)
|
2010-04-06 |
2013-04-30 |
Эдисон Фармасьютикалз, Инк. |
Лечение атаксии-телеангиэктазии
|
|
EP2563352A4
(en)
|
2010-04-27 |
2013-11-13 |
Edison Pharmaceuticals Inc |
FORMULAS FROM CHINESE FOR THE TREATMENT OF EYE DISEASES
|
|
US20120101169A1
(en)
|
2010-07-14 |
2012-04-26 |
Penwest Pharmaceuticals Co. |
Methods of providing anticoagulation effects in subjects
|
|
WO2012019032A1
(en)
|
2010-08-06 |
2012-02-09 |
Ampere Life Sciences, Inc. |
Treatment of mitochondrial diseases with vitamin k
|
|
US20130345312A1
(en)
|
2010-08-06 |
2013-12-26 |
Orion D. Jankowski |
Treatment of mitochondrial diseases with naphthoquinones
|
|
US20120295985A1
(en)
|
2010-11-19 |
2012-11-22 |
Miller Guy M |
Methods for improving blood glucose control
|
|
WO2012154613A1
(en)
|
2011-05-06 |
2012-11-15 |
Edison Pharmaceuticals, Inc. |
Improved process for the preparation of d-alpha-tocotrienol from natural extracts
|
|
WO2012170773A1
(en)
|
2011-06-08 |
2012-12-13 |
Edison Pharmaceuticals, Inc. |
Adjunctive therapy for the treatment of mitochondrial disorders with quinones and naphthoquinones
|
|
WO2012174286A1
(en)
|
2011-06-14 |
2012-12-20 |
Edison Pharmaceuticals, Inc. |
Catechol derivatives for treatment of oxidative stress diseases
|
|
WO2013006736A1
(en)
|
2011-07-06 |
2013-01-10 |
Edison Pharmaceuticals, Inc |
Treatment of leigh syndrome and leigh-like syndrome, including complications of sucla2 mutations, with tocotrienol quinones
|
|
US20150057363A1
(en)
|
2011-07-06 |
2015-02-26 |
Guy M. Miller |
Treatment of methylmalonic aciduria, isovaleric aciduria, and other organic acidurias with tocotrienol quinones
|
|
JP2014520894A
(ja)
|
2011-07-19 |
2014-08-25 |
エジソン ファーマシューティカルズ， インコーポレイテッド |
非アルファトコトリエノールの存在下でのアルファトコトリエノールの選択的酸化のための方法
|
|
EP2892515A1
(en)
|
2012-09-07 |
2015-07-15 |
Edison Pharmaceuticals, Inc. |
Benzoquinone derivatives for treating oxidative stress disorders
|
|
JP6313791B2
(ja)
|
2013-03-08 |
2018-04-18 |
ユニリーバー・ナームローゼ・ベンノートシヤープ |
皮膚科学的使用のためのレゾルシノール化合物
|
|
US9868711B2
(en)
|
2013-03-15 |
2018-01-16 |
Bioelectron Technology Corporation |
Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
|
|
US20140275045A1
(en)
|
2013-03-15 |
2014-09-18 |
Edison Pharmaceuticals, Inc. |
Phenazine-3-one and phenothiazine-3-one derivatives for treatment of oxidative stress disorders
|
|
US9296712B2
(en)
|
2013-03-15 |
2016-03-29 |
Edison Pharmaceuticals, Inc. |
Resorufin derivatives for treatment of oxidative stress disorders
|
|
EP2970158B1
(en)
|
2013-03-15 |
2019-02-20 |
BioElectron Technology Corporation |
Alkyl-heteroaryl substituted quinone derivatives for treatment of oxidative stress disorders
|
|
US9670170B2
(en)
|
2013-03-15 |
2017-06-06 |
Bioelectron Technology Corporation |
Resorufin derivatives for treatment of oxidative stress disorders
|
|
WO2014194292A1
(en)
|
2013-05-31 |
2014-12-04 |
Edison Pharmaceuticals, Inc. |
Carboxylic acid derivatives for treatment of oxidative stress disorders
|